Dexamethasone and Lenacapavir interaction

Dexamethasone and Lenacapavir: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Dexamethasone (Hemady) label · effective 2026-01-09

Major

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers.

Drug interactionsby drug classView label on DailyMed
Major

Avoid coadministration of strong CYP3A4 inhibitors or consider alternative medication that are not strong CYP3A4 inhibitors.

Drug interactionsby drug classView label on DailyMed
Major

If concomitant use of strong CYP3A4 inhibitors cannot be avoided, closely monitor for adverse drug reactions.

Drug interactionsby drug classView label on DailyMed
Moderate

( ‎7.2 ) 7.1 Effect of Other Drugs on HEMADY Strong CYP3A4 inhibitors Coadministration of strong and moderate CYP3A4 inhibitors increased dexamethasone exposure [see Clinical Pharmacology (‎ 12.3 )] , which may increase the risk of adverse reactions [see Warnings and Precautions (‎ 5 ) and Adverse Reactions (‎ 6 )] .

Drug interactionsby drug classView label on DailyMed

From the Lenacapavir (Sunlenca) label · effective 2026-08-27

Major

Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1) ] .

Contraindicationsby drug classView label on DailyMed
Major

Concomitant administration of SUNLENCA is contraindicated with strong CYP3A inducers.

Contraindicationsby drug classView label on DailyMed
Major

Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated [see Contraindications (4) ] .

Drug interactionsby drug classView label on DailyMed
Major

Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended.

Drug interactionsby drug classView label on DailyMed
Moderate

Initiate with the lowest starting dose and titrate carefully while monitoring for safety. ↓ lenacapavir (dexamethasone) Concomitant administration of systemic dexamethasone may result in loss of therapeutic effect of lenacapavir and development of resistance.

Drug interactionsnames DexamethasoneView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.